MoonLake's HS Drug Clears Final FDA Hurdle, Paving Way for September BLA Filing with Strong Efficacy Data
Summary
MoonLake Immunotherapeutics announced a highly positive outcome from its final pre-BLA meeting with the FDA for its hidradenitis suppurativa (HS) program, Nanobody® SLK. The company and FDA aligned on all key submission plans, label strategy, and safety data, with no remaining gaps identified, effectively de-risking the regulatory pathway. Notably, the FDA re-confirmed the acceptability of including MIRA trial data, which showed ~43% HiSCR 75 response rate and ~29 percentage point delta-to-placebo, described as the highest observed values in HS trials to date. This critical milestone paves the way for a BLA submission in adult and adolescent HS by the end of September 2026, with an intent to apply for Priority Review and a potential US launch in H2 2027. Additionally, the company reported Q1 2026 financial results, holding $357.9 million in cash, confirming sufficient capital to fund operations through the end of 2027, further bolstered by a new $400 million non-dilutive debt facility. Investors will now watch for the BLA submission, the Priority Review decision, and upcoming Phase 3 readouts for PsA and adolescent HS in mid-2026.
At the time of this announcement, MLTX was trading at $17.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $5.95 to $62.75. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.